introduction Despite significant advances, metastatic breast cancer (MBC) remains a non-curable disease, with a median overall survival (OS) of 24-36 months for human epidermal growth factor receptor 2 (HER2)-negative MBC patients. Systemic treatment includes chemo-, endocrine, and targeted therapies, according to factors such as hormone receptors, endocrine resistance, visceral crisis, previous adjuvant therapy, and relapse-free interval [1] . However, very few first-line therapies have demonstrated an OS benefit in prospective clinical trials, except for HER2-directed therapies [2] .
Bevacizumab is a monoclonal antibody that inhibits VEGFmediated tumor angiogenesis [3] . Based on results from the first pivotal phase III study (E2100) [4] , the US Food and Drug Administration (FDA) granted accelerated approval to bevacizumab in combination with paclitaxel as first-line treatment for HER2-negative MBC in 2008. The combination showed a 6-month improvement in progression-free survival (PFS) but had no impact on OS. Later, two trials [5, 6] investigating the combination of bevacizumab with other cytotoxic agents (and a global meta-analysis of this strategy [7] ) failed to show an OS improvement and suggested a non-favorable risk-benefit profile. Although the FDA revoked approval of bevacizumab for MBC in 2011, the combination remained approved in several countries, albeit with some restrictions.
Real-world evidence studies are complementary tools for describing drug effectiveness and safety over the entire product life-cycle, and are increasingly important in light of the recent expansion of products granted conditional approval. Health authorities are also interested in real-world data for long-term benefit-risk assessment as well as medico-economic evaluation, requiring improvements in research methods and data quality.
The Epidemiological Strategy and Medical Economics (ESME) program is an academic initiative led by Unicancer, the French network of cancer centers, to centralize real-life data on MBC. The program involves 18 specialized cancer centers managing together over one-third of all breast cancer cases nationwide. Academic or private organizations may query the ESME MBC database for predefined questions, without direct access to the data or involvement in the work program. The primary objective of this first analysis of the database was to describe OS in patients with HER2-negative MBC treated with first-line paclitaxel chemotherapy, with or without bevacizumab.
methods study design
We conducted a non-interventional, retrospective, comparative study to describe the outcome of predefined MBC patients selected in the ESME MBC database. This database gathers individual data from all patients, male or female, ≥18 years, having started an anti-cancer treatment for a metastatic breast carcinoma in 1 of 18 cancer centers participating in the ESME program, from 1 January 2008 to 31 December 2013.
For the present study, patient selection focused on those with HER2-negative MBC who started first-line paclitaxel-based chemotherapy (at least one infusion delivered), with (combination group) or without ( paclitaxel group) bevacizumab. Data were collected until the cut-off date (1 October 2014), death (if this occurred before the cut-off date), or date of last contact (if lost to follow-up).
In compliance with French regulations, the ESME MBC database was authorized by the French data protection authority (authorization no. 1704113) and managed by R&D Unicancer in accordance with current best practice guidelines [8, 9] . The study was approved by an independent ethics committee which waived the requirement for informed consent. A detailed description of the database is available in the supplementary material, available at Annals of Oncology online.
evaluation criteria
The primary end point was OS defined as time (months) between index date (start of first-line chemotherapy) and date of death (any cause). The main secondary end point was PFS defined as time between index date and date of first disease progression or death. Disease progression was defined as appearance of new metastatic site, progression of existing metastasis, local or locoregional recurrence of the primary tumor, discontinuation of chemotherapy and/or targeted therapy due to metastatic progression ( judged by the reference physician), or death from any cause.
statistical analysis
Descriptive statistics [including mean, standard deviation (SD)] were used to summarize patients' initial characteristics at diagnosis of metastatic disease. These characteristics were compared between the two groups using Pearson's χ 2 test or Student t-test, when appropriate; a P value of <0.05 was considered statistically significant. Both OS and PFS were estimated using the KaplanMeier method. Survival curves with associated log-rank tests were generated. Censored data (duration of follow-up and patient status at last contact) were descriptively summarized for the two groups. The reverse Kaplan-Meier method was used to estimate the median follow-up durations [10] . A minimum set of forced variables (prognostic factors) and unforced variables were selected by univariate analysis. The primary analysis was based on multivariate analysis using a Cox model adjusted and stratified for prognostic factors of survival and potential cofounders. Prognostic factors for which the proportional hazards assumption was violated (i.e. significant interaction of covariate with time) were introduced as stratification factors, and factors for which the proportional hazards assumption was verified were included as covariates. Adjusted survival curves were generated using the Breslow Estimator [11] . Power calculations based on the observed sample size for the primary analysis were carried out for OS using the hazard ratio (HR) for death observed between the two groups. PFS was analyzed in a similar way to OS. HRs are presented on a descriptive basis with 95% confidence intervals (CI results patient characteristics and follow-up Of 14 014 patient files identified in the ESME MBC database, 10 605 patients had HER2-negative breast cancer at the time of first MBC diagnosis. Of these, 3426 started a first-line paclitaxelbased chemotherapy: 2127 (62.1%) in the combination group ( paclitaxel with bevacizumab) and 1299 (37.9%) in the paclitaxel group ( paclitaxel without bevacizumab) ( Figure 1 ).
Patients' characteristics at baseline (time of diagnosis of metastatic status) are shown in Table 1 . Compared with the paclitaxel group, patients in the combination group were younger (median age, 55 versus 63 years; P < 0.001), had a lower prevalence of central nervous system metastases (5.3% versus 8.2%; P < 0.001) and lung/pleura metastases (36.8% versus 40.6%; P = 0.025), but had more liver metastases (40.9% versus 35.9%; P = 0.004). They also had fewer metastatic sites (≥3: 28.9% versus 33.6%; P = 0.004) and were less often diagnosed with breast cancer and upfront concomitant metastasis (16.3% versus 24.3%; P < 0.001).
The median follow-up duration was longer in the combination group (33.8 months, 95% CI 31.5-35.4) than in the paclitaxel group (27.2 months, 25.8-29.7). The proportion of patients categorized as 'lost to follow-up' in the combination and paclitaxel groups was 9.4% and 10.2%, respectively (no data available within 9 months before cut-off date) (supplementary Table S1 , available at Annals of Oncology online).
treatment exposure and first-line chemotherapy
The median (±SD) treatment duration with paclitaxel-based chemotherapy was slightly longer in the combination group [5 months (3.45-6.04); n = 2081] than in the paclitaxel group [3.7 months (1.87-5.35); n = 1231]. The median duration of bevacizumab treatment was 5.32 months (3.25-7.92). During first-line treatment, patients were exposed to other therapies, including endocrine therapy, radiotherapy, and chemotherapeutic or targeted agents other than bevacizumab or paclitaxel (Table 1) , usually given as a maintenance strategy and more often in the paclitaxel group: capecitabine (8.7% versus 8.9%), cyclophosphamide (2.5% versus 9.1%), anthracyclines (1.9% versus 8.1%), docetaxel (1.6% versus 3.5%), and others (2.2% versus 6.2%). Chemotherapy was the first treatment received for MBC in 86.5% of patients.
overall survival
In the multivariate analysis, OS adjusted on major prognostic factors was longer for the combination group than for the paclitaxel group, with the median survival times of 27.7 months (95% CI 25.7-29.0) and 19.8 months (18.3-21.0), respectively (HR 0.672; 95% CI 0.601-0.752) (Figure 2 ). Results were consistent in all supportive analyses (Figure 3 ). When the propensity score was considered in the adjusted analyses, OS was statistically significantly different between the two groups (HR 0.700, 95% CI 0.635-0.771). Regarding the analyses of patients case-matched for propensity score at 1% and 2%, HRs were 0.759 (95% CI 0.677-0.851) and 0.761 (0.679-0.854), respectively. All sensitivity analyses yielded similar results as well as analyses conducted in subgroups (Table 2 and supplementary material, available at Annals of Oncology online).
Causes of death are described in supplementary Table S1 , available at Annals of Oncology online, as reported in patients' files.
progression-free survival
In the multivariate analysis, adjusted PFS was significantly longer for the combination group than the paclitaxel group (HR 0 Figure S2 , available at Annals of Oncology online) and sensitivity analyses ( Table 2) .
discussion
The ESME program represents the first large-scale European real-life initiative on MBC, involving more than 14 000 patients with a mean follow-up time of 40.0 months (95% CI 39.2-40.7). 
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In the present analysis, patients who received the combination (paclitaxel plus bevacizumab) had a significantly higher OS compared with those who received paclitaxel (HR 0.672; median, 27.7 versus 19.8 months). PFS was also significantly higher with the combination group, with a more modest beneficial effect (HR 0.739; 8.1 versus 6.4 months). The results showed consistency across all supportive and sensitivity analyses.
Our results on OS in the combination group are in line with those from phase III trials that investigated bevacizumab in combination with chemotherapy as first-line treatment for HER2-negative MBC (E2100, AVADO, and RIBBON-1 [4] [5] [6] ). However, while all three studies showed a benefit on PFS, none demonstrated an OS benefit, nor did a meta-analysis of the data [7] . E2100 is the only study to have investigated bevacizumab in combination with paclitaxel. Having enrolled 722 patients, it showed a higher 1-year OS with the combination compared with paclitaxel alone (81.2% and 73.4%, respectively; P = 0.01) but no significant impact on OS with longer follow-up (HR = 0.88, P = 0.16; median, 26.7 versus 25.2 months). In the present analysis, while OS was in line with that reported in the combination group in E2100, the paclitaxel group, however, had a lower OS (19.8 months) than that obtained in E2100.
Regarding PFS, our results in the combination group are in line with those reported in the above-mentioned trials (stratified HR = 0.60, P < 0.001 in E2100 [4] ) and in the MERiDiAN trial [12] , and with the capecitabine plus bevacizumab combination [13] .
Observational studies, with their larger sample size and longer follow-up, can provide complementary data to help improve the assessment of treatment value obtained within the strict framework of randomized, controlled trials. Indeed, in clinical trials, both longer median time to event and smaller relative size often decrease power for OS analysis compared with PFS, especially in the case of long post-progression survival [14] . In addition, well-known limitations lead to large uncertainty about OS as an indicator of treatment efficacy. A major drawback stems from a weakening of the potential benefits allocated by randomization through the use of maintenance therapies or subsequent lines of treatment following disease progression. Indeed, recent data suggest that maintenance treatment has a positive effect on OS, hindering conclusions [7, 15, 16] . Importantly, some recent oncology guidelines have been developed based on surrogates for survival in the absence of OS benefit [17] . As health authorities require real-life data to reassess therapeutic alternatives in pragmatic settings, carefully designed observational studies are important for bridging the gap between clinical research and clinical practice. Carefully built observational studies from real-world databases should be a useful complement of randomized trials in a near future, through the control of expected therapeutic activities of therapeutic agents, the identification of major medical needs and gaps, but also through improvement of our understanding of the choice of treatment strategies. As well, observational studies might help assessing real-world outcome of recently released agents, although this was not the case for safety with the present database.
The present work has indeed several major strengths. First, rigorous standard screening procedures across all 18 cancer centers and statistical methodology were applied to minimize selection bias. In addition, propensity scores were used to adjust for baseline differences between groups and to reduce the impact of treatment selection bias (see supplementary material, available at Annals of Oncology online). Secondly, the analysis was based on a large number of well-documented cases, with a high level of quality control and exhaustive patient selection across participating centers. An important limitation is that it captures data from patients treated in academic comprehensive cancer centers, making it potentially hazardous to extrapolate results to other institutions. Other limitations are inherent to the retrospective and observational nature of the study design. Particularly, in a non-randomized setting, biases in treatment assignment linked to patient characteristics or underlying disease may be a major driver of different outcomes. In this study, patients' baseline characteristics were carefully scrutinized for factors that might explain treatment assignment and poorer outcome observed in the paclitaxel group. Significant differences were observed, notably a younger age and shorter time between metastatic diagnosis and start of treatment in the combination group. Available data did not include performance status, a key factor for OS [18] ; it was not routinely reported by physicians. Thus, the observed between-group OS difference might just reflect a lower performance status and higher level of co-morbidity in patients assigned to paclitaxel, deliberately chosen in order to minimize the risk of side-effects of the combination. However, this is not supported by the sensitivity analyses (see supplementary material, available at Annals of Oncology online). Of note, observational databases suggest that variability in real-world outcomes in cancer patients not only may be influenced by the selection of medications, but may also reflect the timely intersection of disease status, patient preference, and provider interpretation. Another limitation is that differences in patient monitoring and non-standardized retrospective data collection for disease progression may result in information bias, although a robust data management plan and quality control program were designed to limit this. As for randomized studies, we cannot clearly evaluate the impact of second-line treatments and there might be some imbalance between groups regarding them, although interpretation is very difficult (supplementary Table S2 , available at Annals of Oncology online). Finally, data on comorbidities and safety were not systematically available and documented in the EMR. Nevertheless, we expected them to be potentially highly biased by centers' and physicians' habits. This precludes potential analyses such as those on competing mortality causes, risk/benefits, and, to some extent, propensity.
conclusions
We observed that patients with HER2-negative MBC receiving first-line chemotherapy paclitaxel combined with bevacizumab in a real-life setting have an OS identical to that observed in clinical trials, while patients receiving paclitaxel have a significantly lower OS. Whether the observed difference is linked to the treatment itself, to prescription bias, or to a mixed effect of both cannot be ascertained. Based on the present study, data cannot support extension of current use of bevacizumab in MBC. Further analysis will be carried out to assess the impact of subsequent treatments on OS. The MBC database will be updated on a yearly basis.
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